europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Newsletter
    • Library
Become a member
✕

EuropaBio Statement on the publication of the New European Innovation Agenda

07/07/2022
OTHER
July 7, 2022, Brussels - EuropaBio welcomes the publication of the New European Innovation Agenda (EIA) by the European Commission, which contains initiatives that can contribute to the development of the European biotechnology industry and to deep tech innovation in Europe. The EU should continue to pursue relevant initiatives to make full use of its scientific and industrial excellence to create the necessary conditions for the growth of biotechnology and other innovative industries across Europe.

Several new initiatives proposed under the EIA are set to contribute to move Europe in the right direction, whether it is through allowing innovators to experiment more freely through the creation of regulatory sandboxes, by connecting innovation ecosystems through new regional cooperation structures, improving access to finance for European start-ups and scale-ups, or by attracting and retaining talent in the EU.

Going forward, the EU should focus on legislation that continues to improve an innovation-friendly environment in Europe, facilitating a greater scale of investment and significant global market share originating from Europe. This will further contribute towards tomorrow’s cutting-edge technologies being developed and launched in Europe, dovetailing with initiatives such as the EIA to support the twin green and digital transitions and overall EU sustainability ambitions.

A science-based, proportionate, and predictable policy approach would help leverage the full potential of biotechnology, including new genomic techniques, to benefit citizens, the economy, and the environment. Further promotion of education, training, and skills development to foster European industrial competitiveness and innovation in key enabling technologies (such as biotechnology), will also be critical for Europe’s future, and its ability to achieve strategic autonomy.

Biotechnology already plays and will continue to play a significant role in making European societies healthier, more sustainable, and will help the EU deliver for its citizens in the face of the systemic and global challenges we face in the 21st century.

EuropaBio Statement on the publication of the New European Innovation Agenda


Download

Share
Alexandra Simionca
Alexandra Simionca

Related posts

23/03/2023

Unlocking the Potential of Biotechnology Innovation for Patients


Read more
16/03/2023

Vision, clarity and enabling – the drivers for Europe’s biomanufacturing future


Read more
07/03/2023

Disc Medicine joins EuropaBio: life-changing medicines for patients with hematologic disorders


Read more
06/03/2023

Can the Pharmaceutical Strategy Deliver for Europe?


Read more

Important links

  • Unlocking the Potential of Biotechnology Innovation for Patients
  • Vision, clarity and enabling – the drivers for Europe’s biomanufacturing future

Categories in our Newsroom

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkLegal & Cookies